8- (3- (2- chloro- 10H- phenothiazin- 10- yl)propyl)- 1- thia- 4,8- diazaspiro(4.5)decan- 3- one

01/01/2021 - "In the xenograft model, NSC290956 significantly reduces H358 tumor growth in nude mice by mechanisms similar to those observed in the cells. "
01/23/2018 - "Furthermore, Spiclomazine arrests cell cycle at G2 phase in the cancer cells, without obvious cell-cycle arrest in the normal cells. "
01/23/2018 - "It is worth mentioning that the mutant KRas-driven cancer cells are more sensitive towards Spiclomazine than the wild-type KRas cancer cells. "
01/23/2018 - "Based on our model prediction, Spiclomazine freezing the intermediate conformation of activated Ras is central to cancer therapeutics. "
01/23/2018 - "Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer."

01/01/2013 - "Herein, this current study showed that spiclomazine treatment caused a reduction in viability in pancreatic carcinoma cell lines CFPAC-1 and MIA PaCa-2 in vitro. "
01/23/2018 - "Taken together, Spiclomazine is a selective inhibitor for mutant KRas-driven pancreatic cancer."
01/01/2013 - "It was notable in this regard that, compared with pancreatic carcinoma cells, normal human embryonic kidney (HEK-293) and liver (HL-7702) cells were more resistant to the antigrowth effect of spiclomazine. "
01/01/2013 - "Spiclomazine induces apoptosis associated with the suppression of cell viability, migration and invasion in pancreatic carcinoma cells."
01/23/2018 - "Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer."

01/01/2021 - "Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer."
01/01/2021 - "In mutant KRas-driven non-small-cell lung cancer (NSCLC) model system, NSC290956 effectively suppresses the KRas-GTP state and gives pharmacological KRas inhibition with concomitant blockages of both the MAPK-ERK and AKT-mTOR pathways. "